Abstract
This mini review explores the evolving landscape of metabolic disturbances and their impact on female reproductive outcomes, with a particular focus on emerging molecular biomarkers and novel metabolic phenotypes. Metabolic health plays a pivotal role in female reproductive function, with well-established endocrine-metabolic disorders, such as polycystic ovary syndrome, obesity, and diabetes mellitus, known to impair fertility. This review explores these conditions, including less commonly studied phenotypes like normal weight obesity, metabolically obese normal weight, and metabolically healthy obesity, which challenge traditional diagnostic frameworks by presenting metabolic risk independent of body mass index. These underrecognized profiles can adversely affect ovarian physiology, endometrial receptivity, and assisted reproductive technology outcomes. The review further highlights potential biomarkers, including bile acids and advanced glycation end-products, as promising diagnostic and therapeutic targets. By integrating insights from metabolic regulation, endocrinology, and reproductive biology, this article emphasizes the need for a more nuanced, individualized approach to fertility assessment and treatment. Understanding these interconnections is vital for advancing personalized medicine, particularly in addressing unexplained infertility and optimizing assisted reproductive technology success.
Introduction
Infertility affects 8%–12% of women of reproductive age () and is a growing global concern, underscored by over 1 million assisted reproductive technologies (ART) cycles reported in 40 European countries in 2019 (Smeenk et al., 2023). Despite ongoing efforts, ART success rates remain low at around 30% (Smeenk et al., 2023), largely due to the complex and multifactorial nature of infertility etiologies. Recent evidence highlights that metabolic disorders, marked by insulin resistance, low-grade systemic inflammation, abdominal obesity, adipose tissue dysfunction and dyslipidemia, commonly observed in obese women and women with polycystic ovary syndrome (PCOS), are directly implicated in reduced fertility (; ; Zhuang et al., 2024). Obesity and overweight are intricately linked to diminished pregnancy rates, heightened demands for gonadotrophins, and elevated occurrences of miscarriage (; ; Qi et al., 2022). Moreover, a high BMI correlates with adverse pregnancy outcomes, including gestational diabetes, hypertension, and preterm labor (; Šimják et al., 2018; ). The underlying mechanisms are versatile and encompass hormonal alterations due to hypothalamic-pituitary-ovarian axis disruption, derailed metabolism (insulin resistance, hyperglycemia, dyslipidemia), chronic inflammation (elevated levels of proinflammatory cytokines, e.g., IL-6, IL-1β, TNF-α) and mitochondrial dysfunction (enhanced oxidative stress, apoptosis, mitochondrial DNA damage) that ultimately induce alterations in the ovarian follicle microenvironment, that have been extensively reviewed elsewhere (Silvestris et al., 2018; ; Muhammad et al., 2023). Alarmingly, the World Obesity Federation highlights a striking uptick in the prevalence of maternal obesity within developed nations, which is projected to reach 45%–50% by 2030 (Phelps et al., 2024). With obesity and related metabolic disorders on the rise, assessing metabolic risk factors is essential to optimize infertility treatments and personalize strategies for improving pre-conception health. This article reviews current evidence on how metabolic health influences female fertility, highlighting emerging perspectives and under-studied phenotypes, normal weight obesity (NWO), metabolically obese normal weight (MONW), and metabolically healthy obesity (MHO), in relation to reproductive outcomes. Additionally, it explores the potential of emerging molecules such as bile acids (BAs) and advanced glycation end-products (AGEs) as biomarker candidates, and concludes with an overview of current research gaps and future directions.
Emerging metabolic phenotypes and female fertility
Based on the World Health Organization guidelines, a body mass index (BMI) equal to or exceeding 25 kg/m2 stratifies overweight and a BMI above 30 kg/m2 obesity, respectively (). The use of BMI remains the foremost widely accepted measure for evaluating overweight and obesity. However, the diagnostic utility of BMI is significantly limited due to its inability to differentiate between fat and lean mass, which may lead to misclassifications since individuals sharing the same BMI may exhibit markedly distinct fat distributions. Women tend to face a higher likelihood of being underrecognized for overweight or obesity based on BMI criteria alone (Peterson et al., 2014). This lack of discrimination may hinder accurate assessments of adiposity associated health risks and necessitates the integration of additional measures, such as waist circumference or percentage of body fat (%BF). Emerging data indicates that central adiposity (higher waist-hip ratio) predicts lower fecundability and live birth after in-vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) independent of BMI (; Ye et al., 2025). Notably, recent evidence suggests that the negative impact of central obesity is even more pronounced in women with lower BMI (Ye et al., 2025). Based on the data of the National Health and Nutrition Examination Survey, threshold values for %BF were established by evaluating its correlation with the risk of developing metabolic syndrome at various BMI cut-off points. For women, the %BF thresholds were defined at 24%, 31%, 37%, and 43%, which correspond to BMI values of 18.5, 25, 30, and 35 kg/m2, respectively (Zhu et al., 2003). In this context, studies have highlighted the importance of differentiating individuals with NWO from those who are MONW. NWO is characterized by a BMI in the normal range (18.5–24.9 kg/m2) but elevated %BF (Mohammadian Khonsari et al., 2022). MONW individuals present a normal BMI but high %BF and obesity-related metabolic disturbances, such as excess visceral fat, insulin resistance, dyslipidemia, hypertension, and elevated risk of type 2 diabetes mellitus (T2D) and cardiovascular events (Pluta et al., 2022). In NWO individuals, metabolic abnormalities are often subtler and frequently undetected, however, this phenotype is associated with an elevated risk of metabolic syndrome and cardiometabolic disease compared with individuals of normal BMI and %BF (Table 1) (Mohammadian Khonsari et al., 2022). A cross-sectional study in Korea found that men and women with NWO were 2.7 and 1.9 times more likely to develop metabolic syndrome, respectively, compared to those with a normal BMI and %BF (). A study comparing 326 males and 641 females revealed that 26% of males and 38% of females within the normal BMI range had a %BF above the respective cutoffs of 25% and 35% (). Furthermore, they showed that even a slightly elevated waist circumference (>88 cm in women) can identify 60% of NWO individuals at risk for metabolic syndrome (). A recent study on NWO found that 15.8% of 469 normal-weight women had elevated %BF (≥31%), which was associated with reduced reproductive outcomes, including lower antral follicle counts, numbers of retrieved oocytes, fertilized oocytes, high-quality embryos on day 3 post fertilization and cleaved embryos (Yao et al., 2024). Interestingly, these findings stand in contrast to previous research, which failed to identify disparities in antral follicle counts or the quantity of retrieved oocytes between women categorized by %BF status. (). Both studies found no differences in early pregnancy outcomes, including implantation, biochemical pregnancy, and clinical pregnancy rates, when women were stratified by %BF (; Yao et al., 2024). In a large BMI-stratified IVF cohort, MONW had lower biochemical pregnancy rates than metabolically healthy normal-weight counterparts, with high blood pressure identified as a significant risk factor for this outcome (). However, variations in cardiometabolic risk factors within the same BMI category appeared to have limited impact on live-birth rates ().
TABLE 1
| Phenotype | Characterization | Increased risk ofa |
|---|---|---|
| NWO (Mohammadian Khonsari et al., 2022) | BMI 18.5–24.9 kg/m2 BF% >32 Central obesity | hyperglycemia, insulin resistance, hypertension, dyslipidemia, metabolic syndrome |
| MONW (Ruderman et al., 1998; Pluta et al., 2022) | BMI 18.5–24.9 kg/m2 BF% ≥32 Excess visceral fat, hyperinsulinemia and insulin resistance, dyslipidemia, PCOS | metabolic syndrome, T2D cardiovascular events |
| MHO (Smith et al., 2019) | BMI ≥25 kg/m2, <35 kg/m2 Absence of metabolic abnormalities or diagnosis ≤2 of 5 metabolic syndrome components | Cardiometabolic disturbances |
Criteria for defining NWO, MONW and MHO phenotypes.
compared to metabolically healthy normal weight individuals.
Importantly, the prevalence of NWO and MONW in women varies with age, showing that advancing age and concomitant menopause leads to an increased risk of metabolic abnormalities (Zheng et al., 2020; ). One explanation is that estrogen may act as a protective factor in maintaining metabolic health in normal-weight females, since the loss of estrogen signaling in menopausal women leads to a preferential increase in visceral fat ().
Of further specific interest are obese individuals demonstrating minimal or no metabolic disturbances, a condition termed MHO (Table 1) (Smith et al., 2019). Large-scale genomic studies have identified genetic variants associated with favorable cardiometabolic profiles despite increased adiposity, often located in or near genes involved in adipogenesis, fat distribution and insulin signaling, suggesting a genetic basis for this phenotype (). A recent study of women aged 20–45 found that both metabolically healthy and unhealthy individuals with obesity had similar infertility risk, suggesting obesity itself is a key factor regardless of metabolic status. However, metabolically unhealthy obese individuals exhibited a significantly pronounced risk of infertility compared to MHO individuals (Tang et al., 2023). Similarly, the S-PRESTO preconception cohort found reduced fecundability associated with metabolic disease, predominantly in overweight and obese women, whereas no reduction was observed in those with metabolically healthy profiles by either metabolic syndrome criteria or HOMA-IR (). Complementary plasma proteome analysis revealed that reproductive system development pathways were significantly downregulated in MHO individuals compared to lean healthy controls (Mir et al., 2025). In summary the current body of literature indicates that obesity, irrespective of metabolic health, is associated with impaired fertility, suggesting that weight management should be a priority in reproductive health strategies, even among metabolically healthy individuals. While there is extensive research on the impact of obesity on fertility, the specific effects of NWO, MONW and MHO on fertility, in vitro embryo development and pregnancy outcomes remain areas that require further investigation.
Metabolic disorders and metabolite profiles in female infertility
PCOS is a common endocrine disorder affecting 4%–21% of women of reproductive age and is a leading cause of anovulatory infertility (). Obesity, present in 50%–80% of PCOS cases, plays a central role in the pathophysiology of PCOS by promoting insulin resistance, which affects approximately 44%–70% of affected women (Sam, 2007; ). However, the interplay between obesity and PCOS is complex and appears to be bidirectional: it remains unclear whether PCOS predisposes women to weight gain or if obesity itself initiates the metabolic disturbances that culminate in PCOS. In fact, both obese and non-obese women with PCOS exhibit more adverse metabolic profiles and increased visceral adiposity compared to age- and BMI-matched controls. Non-obese individuals often display features of the MONW phenotype, including hyperinsulinemia, insulin resistance, and elevated intra-abdominal fat mass (Ruderman et al., 1998; Satyaraddi et al., 2019). Moreover, insulin resistance is present in approximately 80% of obese PCOS patients and even in 20% of their nonobese counterparts, underscoring that significant metabolic risk persists regardless of BMI (Satyaraddi et al., 2019). Similarly, women with diabetes encounter reproductive health issues including a higher prevalence of oligomenorrhea, irregular menses, subfertility, adverse pregnancy outcomes, and early menopause (Thong et al., 2020; Qin et al., 2023). Since these reproductive issues are partially attributed to concomitant obesity and PCOS, studies exclusively discerning the impact of diabetes are of great importance. Women with T2D may experience equal or greater fertility risks than those with type 1 diabetes mellitus (T1D), despite a shorter disease duration (Thong et al., 2020; ). Aberrant insulin actions and hyperglycemia are significant drivers that contribute to ovarian dysfunction (). The ovary expresses insulin receptors in granulosa cells, theca cells, and stromal tissue. Insulin signaling, through insulin receptors and insulin-like growth factor-1 receptors, can mimic follicle-stimulating hormone (FSH) and luteinizing hormone (LH) actions, a phenomenon known as the co-gonadotropin effect, enhancing androgen, estrogen, and progesterone production (). By mimicking gonadotropins, insulin drives early follicular growth and contributes to polycystic ovarian morphology (). Furthermore, in human granulosa cells, insulin promotes free fatty acid synthesis and synergizes with luteinizing hormone to upregulate key sterol-regulatory genes (Sekar et al., 2000; Richardson et al., 2005). In obese PCOS patients with insulin resistance, follicular fluid contains significantly elevated levels of mono- and polyunsaturated fatty acids, which are linked to reduced oocyte quality and increased embryo fragmentation (Niu et al., 2014). Supporting these findings, PCOS granulosa cells exhibit dysregulated expression of genes involved in lipid metabolism, fatty acid biosynthesis, and steroidogenesis, including upregulation of lipoxygenases that promote pro-inflammatory lipid mediator production (; Liao et al., 2022).
As key metabolic regulators of glucose and lipid homeostasis and modulators of systemic inflammatory balance bile acids (BAs) have emerged as crucial biomolecules in PCOS pathophysiology (). Since abnormal circulating BA profiles are associated with metabolic disorders, including obesity and T2D (; Qi et al., 2021), and complications and diseases during pregnancy (), there is a growing interest in the underlying molecular mechanisms and the establishment of BAs as biological markers to determine pathological changes. In PCOS patients, an elevation of distinct BA classes and direct associations of BA species with insulin and androgen levels were demonstrated (Zhang et al., 2019; Yu et al., 2023). Moreover, shot-gun sequencing of stool samples in PCOS identified a gut microbiota imbalance linked to reduced glycine- and taurine-conjugated BA species (Qi et al., 2019). Fecal microbiota transplantation from PCOS patients induced ovarian dysfunction, insulin resistance, disrupted BA metabolism and infertility, alongside reduced interleukin-22 secretion in mice. BA treatment stimulated IL-22 production and ameliorated PCOS features, highlighting gut microbiota, BA metabolism and IL-22 modulation as potential therapeutic targets (Qi et al., 2019).
Chronic hyperglycemia further promotes the formation of advanced glycation end-products (AGEs). AGEs are heterogeneous and nondegradable molecules formed endogenously or ingested through diet, via non-enzymatic reactions between reducing sugars and free amino groups of proteins, lipids, or nucleic acids, disrupting the normal function of these molecules. Accumulation of AGEs induces tissue damage through receptor-independent binding to the extracellular matrix or receptor-dependent activation of receptor for advanced glycation end-products (RAGE), both of which trigger inflammatory and oxidative stress responses (). Additionally, the soluble receptor for AGEs (sRAGE) circulates systemically and acts as a decoy, mitigating AGE-induced damage by preventing their interaction with RAGE (Merhi, 2014). In follicular fluid, sRAGE protein levels were directly associated with the number of oocytes, follicles, ovarian sensitivity index, embryonic development, and successful clinical pregnancy outcomes in women undergoing ART, proposing sRAGE levels as a predictor for ART outcomes (Merhi et al., 2014; Nejabati et al., 2017; Li et al., 2017). Accordingly, the presence of AGEs in serum and follicular fluid of women undergoing ART has been significantly correlated with poor follicular and embryonic development, as well as a reduced likelihood of achieving an ongoing pregnancy (). Further, overweight and obese women have significantly lower serum sRAGE concentrations when compared with normal-weight women undergoing ART (Merhi et al., 2014). This finding is in line with previous studies demonstrating low plasma sRAGE levels in obese women and diabetic patients, which are associated with high BMI, blood pressure-, triglyceride-, HbA1c-levels, an increased insulin resistance index and enhanced thromboxane biosynthesis, potentially contributing to obesity-related metabolic and vascular disease (; Vazzana et al., 2012). An in vitro study examining the impact of AGEs on insulin signaling and glucose transport using a human ovarian granulosa cell line demonstrated that glycated albumin inhibits PI3K-specific AKT phosphorylation and prevents Glut-4 translocation to the cell membrane, indicating that intra-follicular accumulation of AGEs may interfere with physiological functions of granulosa cells contributing to impaired follicular development (). Immunohistochemical analysis has shown elevated levels of AGEs and RAGE in granulosa and theca cells of women with PCOS and demonstrated a direct association between hyperandrogenism and AGEs in the condition (; ). Of note, administration of the hydrophilic tertiary BA tauroursodeoxycholic acid, a clinically used endoplasmic reticulum stress inhibitor, significantly reduced RAGE and AGE expression in granulosa cells and decreased the number of atretic follicles in PCOS mice (; Yuan et al., 2024).
Discussion
The presence of hormonal and metabolic derailments as seen in PCOS, diabetes, NWO, MONW, and MHO underscores the multifaceted nature of infertility etiologies. Unexplained infertility in approximately 15% of couples further emphasizes the need to investigate less apparent disease patterns and delve into molecular pathways influencing female fertility (Romualdi et al., 2023). Further investigation of NWO, MONW, and MHO phenotypes in reproductive biology is essential, as limited research exists and these conditions are often overlooked, underscoring the need to incorporate comprehensive metabolic assessments into routine clinical care. Women exhibiting a normal BMI are frequently underdiagnosed as studies have shown that approximately 40% of 641 screened women had a BF% above the recommended cutoffs (). Prospective epidemiological studies are essential to validate these findings and examine the long-term impact of NWO, MONW, and MHO on female fertility.
PCOS diagnosis involves multiple markers, including androgen levels and insulin resistance indicators, to characterize the syndrome’s phenotype. Women with PCOS also display adverse lipid profiles and elevated cardiovascular risk, emphasizing the need for targeted metabolic interventions. In this context, BAs have emerged as potential diagnostic biomarkers and novel systemic signaling molecules (Vítek and Haluzík, 2016; ). Particularly pharmacological strategies to modulate the activity of the nuclear BA receptor Farnesoid X Receptor and the G-protein coupled BA receptor TGR5 holds promise for treating fatty liver diseases, obesity, diabetes, and related disorders (). Importantly, the composition of BAs as well as the level of total BAs in follicular fluid have been reported to affect follicular maturation and steroidogenesis in different animal models (Takae et al., 2019; Wei et al., 2022; Zhu et al., 2025). Although promising preclinical evidence supports a significant impact of BAs on the intrafollicular milieu in PCOS, more detailed basic research utilizing human in-vitro models are necessary to establish the efficacy of specific BA-targeting interventions.
Moreover, chronic hyperglycemia, oxidative stress, and chronic low-grade inflammation are key factors known to drive the endogenous formation of AGEs. These compounds have been implicated in the pathogenesis and progression of numerous chronic diseases, including T2D, cardiovascular disease, Alzheimer’s disease, and inflammatory bowel diseases (Perrone et al., 2020; ). The potential of anti-AGE strategies, including agents such as metformin, to alleviate AGE-related dysfunctions in PCOS has been demonstrated (Merhi et al., 2019). Furthermore, treatment with tauroursodeoxycholic acid, has shown promise in reducing AGE and RAGE expression and improving ovarian health in PCOS models (). The mechanisms through which anti-AGE interventions may exert their effects include reducing oxidative stress, improving insulin sensitivity, and modulating inflammatory pathways, which are critical in the management of PCOS. Understanding the AGE-RAGE/sRAGE axis in ovarian dysfunction, especially in women with PCOS, may enhance our understanding of pathologic female reproductive mechanisms. Despite the critical role of AGEs in various disease mechanisms, there is currently no standardized detection method for these compounds, nor is there routine monitoring in clinical practice. Advancing our understanding of AGEs' formation and their pathological impacts could pave the way for improved diagnostic and therapeutic strategies.
Research gaps
Beyond BMI—better phenotyping
Given BMI’s limitations as a proxy for adiposity and metabolic disease risk, adjunct anthropometrics (e.g., waist-to-hip ratio) and body-composition measures (e.g., %BF) may offer clinically useful refinement. Further, rigid BMI-based criteria for offering or denying IVF may restrict equitable access without evidence of clinical benefit. Thresholds (often ≥35–40 kg/m2) vary widely across programs and are largely grounded in observational associations between higher BMI, lower ART success, and greater obstetric risk rather than randomized evidence (Penzias et al., 2021).
Insulin resistance—Standardize and stratify
Insulin resistance, prevalent in PCOS and obesity-related infertility, is inconsistently defined in the literature, with most studies using surrogate indices (e.g., HOMA-IR, QUICKI, Belfiore’s index) that vary in accuracy and underperform the euglycemic–hyperinsulinemic clamp, particularly in lean women (; ). This heterogeneity limits comparability, obscures prevalence in ART populations, and hampers reproducibility of outcome associations. Standardized, cardiometabolic-risk–based and age-adjusted definitions, potentially integrating biomarkers such as insulin growth factor binding protein, adiponectin and ferritin combined with surrogate indices (; ), could improve diagnostic precision and guide metabolic optimization in ART.
Lifestyle, weight-loss and pharmacotherapy interventions before ART
Major societies (European Society of Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM)) recommend lifestyle interventions for individuals with overweight/obesity to reduce weight, central adiposity, and insulin resistance. However, randomized controlled trails and meta-analyses indicate that pre-IVF weight-loss programs (diet/exercise ± medication) improve interim outcomes (e.g., unassisted conception) but have inconsistent or no effect on live birth for women proceeding to IVF (Penzias et al., 2021; ). Pre-ART metabolic pharmacotherapies (metformin, anti-obesity pharmacotherapy including GLP-1 receptor agonists) are supported by small, heterogeneous studies that suggest potential benefit by emphasizing surrogate endpoints (oocyte yield, biochemical pregnancy) but require confirmation in large randomized controlled trails powered for live birth and safety ().
Future directions
Next-generation personalization in reproductive medicine will likely come from integrating multi-omics with clinical workflows, potentially improving non-invasive prediction of oocyte competence and embryo viability. Metabolomics of follicular fluid, serum, and embryo culture media can yield dynamic snapshots of energy metabolism, oxidative balance and profile metabolites acting as crucial bioactive signaling molecules (; ; Zhang et al., 2025). Standardized sampling/analytics and prospective validation, ideally supported by machine-learning, are essential to develop reliable tools that link metabolic profiles with clinical outcomes.
Further, the gut microbiota is a central regulator of female reproductive health. The bidirectional “gut–reproductive axis,” mediated by interconnected immune, metabolic, and neuroendocrine networks, facilitates communication between the intestinal microbiota and reproductive organs (Moustakli et al., 2025). Dysbiosis, marked by altered short-chain fatty acid profiles, disrupted BA metabolism, and impaired gut barrier integrity, can perturb host energy balance, promote chronic inflammation, and contribute to metabolic disorders such as PCOS and obesity (Qi et al., 2019; Yao et al., 2023; Moustakli et al., 2025). Strategies to restore a healthy gut microbial profile, via dietary modification, prebiotics, probiotics, or targeted microbial therapeutics, hold promise for improving metabolic homeostasis and reproductive outcomes, though robust interventional evidence remains limited. Future research should focus on robust studies establishing causal relationships between the intestinal microbiome and reproductive disorders.
Lastly, pharmacogenetics represents an emerging avenue for personalization in ART, with significant potential to optimize drug selection and dosing in ovarian stimulation and ovulation induction. Variants in FSH and LH receptor genes have been shown to influence ovarian response to standard stimulation protocols, and early evidence indicates that genotype-guided gonadotropin selection may enhance cumulative pregnancy and live birth rates (; ). These findings warrant confirmation in randomized controlled trials and may ultimately enable tailoring of stimulation regimens to each patient’s metabolic–hormonal profile (Figure 1).
FIGURE 1
Statements
Author contributions
NB: Writing – original draft, Writing – review and editing. KB: Writing – original draft, Writing – review and editing. HF: Writing – original draft, Writing – review and editing.
Funding
The author(s) declare that financial support was received for the research and/or publication of this article. The study is funded through external research funding from the Clinical Department of Obstetrics at the University Hospital Graz, Medical University of Graz.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Abbreviations
AGE, Advanced glycation end-product; ART, Assisted reproductive technologies; BA, Bile acid; %BF, Body fat percentage; BMI, Body mass index; MHO, Metabolically healthy obesity; MONW, Metabolically obese normal weight; NWO, Normal weight obesity; PCOS, Polycystic ovarian syndrome; T1D, Type 1 diabetes mellitus; T2D, Type 2 diabetes mellitus; IVF/ICSI, In-vitro fertilization/intracytoplasmic sperm injection; RAGE, Receptor for advanced glycation end-products; FSH, Follicle-stimulating hormone; LH, Luteinizing hormone.
References
1
Alizadeh Moghadam MasoulehA.Eftekhari-YazdiP.Ebrahimi SadrabadiA.Jafarzadeh EsfehaniR.ToblerM.SchuchardtS.et al (2025). Embryo metabolism as a novel non-invasive preimplantation test: nutrients turn over and metabolomic analysis of human spent embryo culture media (SECM). Hum. Reprod. Update, dmaf015. 10.1093/HUMUPD/DMAF015
2
AzharyJ. M. K.HaradaM.KunitomiC.KusamotoA.TakahashiN.NoseE.et al (2020). Androgens increase accumulation of advanced glycation end products in granulosa cells by activating ER stress in PCOS. Endocrinology161, bqaa015. 10.1210/ENDOCR/BQAA015
3
Biernacka-BartnikA.KocełakP.OwczarekA. J.ChoręzaP. S.MarkuszewskiL.MadejP.et al (2023). The cut-off value for HOMA-IR discriminating the insulin resistance based on the SHBG level in women with polycystic ovary syndrome. Front. Med. (Lausanne)10, 1100547. 10.3389/FMED.2023.1100547
4
BrismarK.HildingA.AnsurudeenI.FlyvbjergA.FrystykJ.ÖstensonC. G. (2023). Adiponectin, IGFBP-1 and -2 are independent predictors in forecasting prediabetes and type 2 diabetes. Front. Endocrinol. (Lausanne)13, 1092307. 10.3389/fendo.2022.1092307
5
BroughtonD. E.MoleyK. H. (2017). Obesity and female infertility: potential mediators of obesity’s impact. Fertil. Steril.107, 840–847. 10.1016/J.FERTNSTERT.2017.01.017
6
BrouwersL.KosterM. P. H.Page-ChristiaensG. C. M. L.KempermanH.BoonJ.EversI. M.et al (2015). Intrahepatic cholestasis of pregnancy: maternal and fetal outcomes associated with elevated bile acid levels. Am. J. Obstet. Gynecol.212, 100.e1–e7. 10.1016/j.ajog.2014.07.026
7
ChambersG. M.DyerS.Zegers-HochschildF.de MouzonJ.IshiharaO.BankerM.et al (2021). International committee for monitoring assisted reproductive technologies world report: assisted reproductive technology, 2014. Hum. Reprod.36, 2921–2934. 10.1093/HUMREP/DEAB198
8
ConfortiA.Di GirolamoR.GuidaM.AlviggiC.CasariniL. (2025). Pharmacogenomic of LH and its receptor: are we ready for clinical practice?Reproductive Biol. Endocrinol.23, 29. 10.1186/S12958-025-01359-2
9
Diamanti-KandarakisE.DunaifA. (2012). Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr. Rev.33, 981–1030. 10.1210/er.2011-1034
10
Diamanti-KandarakisE.ChatzigeorgiouA.PapageorgiouE.KoundourasD.KoutsilierisM. (2016). Advanced glycation end-products and insulin signaling in granulosa cells. Exp. Biol. Med.241, 1438–1445. 10.1177/1535370215584937
11
DingL.LinX.PanP.LiY.ChenW.HeL.et al (2025). Does metabolic status associate with IVF outcomes in women within similar body mass index category: evidence from a large cohort study. J. Diabetes17, e70132. 10.1111/1753-0407.70132
12
DornellesV. C.HentschkeM. R.BadalottiM.TelökenI. B.TrindadeV. D.CunegattoB.et al (2022). The impact of body mass index on laboratory, clinical outcomes and treatment costs in assisted reproduction: a retrospective cohort study. BMC Womens Health22, 479–8. 10.1186/s12905-022-02036-x
13
DupontJ.ScaramuzziR. J. (2016). Insulin signalling and glucose transport in the ovary and ovarian function during the ovarian cycle. Biochem. J.473, 1483–1501. 10.1042/BCJ20160124
14
FiorucciS.DistruttiE.CarinoA.ZampellaA.BiagioliM. (2021). Bile acids and their receptors in metabolic disorders. Prog. Lipid Res.82, 101094. 10.1016/J.PLIPRES.2021.101094
15
FleishmanJ. S.KumarS. (2024). Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets. Signal Transduct. Target. Ther.9 (1), 97–51. 10.1038/s41392-024-01811-6
16
GargD.MerhiZ. (2016). Relationship between advanced glycation end products and steroidogenesis in PCOS. Reproductive Biol. Endocrinol.14, 71. 10.1186/s12958-016-0205-6
17
Gayoso-DizP.Otero-GonzálezA.Rodriguez-AlvarezM. X.GudeF.GarcíaF.De FranciscoA.et al (2013). Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study. BMC Endocr. Disord.13, 47. 10.1186/1472-6823-13-47
18
GonnellaF.KonstantinidouF.Di BerardinoC.CapacchiettiG.PesericoA.RussoV.et al (2022). A systematic review of the effects of high-fat diet exposure on oocyte and follicular quality: a molecular point of view. Int. J. Mol. Sci.23, 8890. 10.3390/ijms23168890
19
HelvaciN.YildizB. O. (2024). Polycystic ovary syndrome as a metabolic disease. Nat. Rev. Endocrinol.21, 230–244. 10.1038/S41574-024-01057-W
20
HetemäkiN.MikkolaT. S.TikkanenM. J.WangF.HämäläinenE.TurpeinenU.et al (2021). Adipose tissue estrogen production and metabolism in premenopausal women. J. Steroid Biochem. Mol. Biol.209, 105849. 10.1016/j.jsbmb.2021.105849
21
HjelmérI.NilssonM.HenicE.JędrzejczakP.NenonenH.OzegowskaK.et al (2025). FSH receptor N680S genotype-guided gonadotropin choice increases cumulative pregnancy and live birth rates after in vitro fertilization. Front. Endocrinol. (Lausanne)16, 1576090. 10.3389/fendo.2025.1576090
22
HoodR. B.LiangD.TanY.FordJ.SouterI.JonesD. P.et al (2022). Characterizing the follicular fluid metabolome: quantifying the correlation across follicles and differences with the serum metabolome. Fertil. Steril.118, 970–979. 10.1016/j.fertnstert.2022.07.023
23
HuD.HuangB.XiongM.YaoJ.YangS.WuR.et al (2022). Impact of elevated body mass index on cumulative live birth rate and obstetric safety in women undergoing assisted reproductive technology. Sci. Rep.12, 18858. 10.1038/s41598-022-23576-0
24
HuangL. O.LoosR. J. F.KilpeläinenT. O. (2018). Evidence of genetic predisposition for metabolically healthy obesity and metabolically obese normal weight. Physiol. Genomics50, 169–178. 10.1152/physiolgenomics.00044.2017
25
JeongH. G.ChoS.RyuK. J.KimT.ParkH. (2024). Effect of weight loss before in vitro fertilization in women with obesity or overweight and infertility: a systematic review and meta-analysis. Sci. Rep.14, 6153. 10.1038/S41598-024-56818-4
26
JinnoM.TakeuchiM.WatanabeA.TeruyaK.HirohamaJ.EguchiN.et al (2011). Advanced glycation end-products accumulation compromises embryonic development and achievement of pregnancy by assisted reproductive technology. Hum. Reprod.26, 604–610. 10.1093/HUMREP/DEQ388
27
KimJ.PatounakisG.JuneauC.MorinS.NealS.BerghP.et al (2021). The Appraisal of Body Content (ABC) trial: increased male or female adiposity does not significantly impact in vitro fertilization laboratory or clinical outcomes. Fertil. Steril.116, 444–452. 10.1016/j.fertnstert.2020.12.037
28
KimJ.KangS.KangH. (2023). Normal-weight obesity and metabolic syndrome in Korean adults: a population-based cross-sectional study. Healthcare11, 2303–2311. 10.3390/HEALTHCARE11162303
29
KotlyarA. M.SeiferD. B. (2023). Women with PCOS who undergo IVF: a comprehensive review of therapeutic strategies for successful outcomes. Reproductive Biol. Endocrinol.21, 70. 10.1186/S12958-023-01120-7
30
KoyamaH.ShojiT.YokoyamaH.MotoyamaK.MoriK.FukumotoS.et al (2005). Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler. Thromb. Vasc. Biol.25, 2587–2593. 10.1161/01.ATV.0000190660.32863.cd
31
KwintkiewiczJ.GiudiceL. C. (2009). The interplay of insulin-like growth factors, gonadotropins, and endocrine disruptors in ovarian follicular development and function. Semin. Reprod. Med.27, 43–51. 10.1055/s-0028-1108009
32
LahavY.KfirA.GepnerY. (2023). The paradox of obesity with normal weight; a cross-sectional study. Front. Nutr.10, 1173488. 10.3389/fnut.2023.1173488
33
LiT.ChiangJ. Y. L. (2014). Bile acid signaling in metabolic disease and drug therapy. Pharmacol. Rev.66, 948–983. 10.1124/pr.113.008201
34
LiY.-J.ChenJ.-H.SunP.LiJ.-J.LiangX.-Y. (2017). Intrafollicular soluble RAGE benefits embryo development and predicts clinical pregnancy in infertile patients of advanced maternal age undergoing in vitro fertilization. J. Huazhong Univ. Sci. Technol. Med. Sci.37, 243–247. 10.1007/s11596-017-1722-z
35
LiS.ChuQ.MaJ.SunY.TaoT.HuangR.et al (2017). Discovery of novel lipid profiles in pcos: do insulin and androgen oppositely regulate bioactive lipid production?. J. Clin. Endocrinol. Metab.102, 810–821. 10.1210/jc.2016-2692
36
LiM. C.Mínguez-AlarcónL.ArvizuM.ChiuY. H.FordJ. B.WilliamsP. L.et al (2019). Waist circumference in relation to outcomes of infertility treatment with assisted reproductive technologies. Am. J. Obstet. Gynecol.220, 578.e1–578.e13. 10.1016/J.AJOG.2019.02.013
37
LiaoB.QiX.YunC.QiaoJ.PangY. (2022). Effects of androgen excess-related metabolic disturbances on granulosa cell function and follicular development. Front. Endocrinol. (Lausanne)13 (1). 10.3389/FENDO.2022.815968
38
LiuB.XuG.SunY.DuY.GaoR.SnetselaarL. G.et al (2019). Association between maternal pre-pregnancy obesity and preterm birth according to maternal age and race or ethnicity: a population-based study. Lancet Diabetes Endocrinol.7, 707–714. 10.1016/S2213-8587(19)30193-7
39
LiznevaD.SuturinaL.WalkerW.BraktaS.Gavrilova-JordanL.AzzizR. (2016). Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil. Steril.106, 6–15. 10.1016/J.FERTNSTERT.2016.05.003
40
LobsteinT.Jackson-LeachR.PowisJ.BrinsdenH.GrayM. (2023). World obesity altas.
41
LoyS. L.ChanD. W. K.KuC. W.CheungY. B.GodfreyK. M.TanK. M. L.et al (2022). Metabolic health status and fecundability in a Singapore preconception cohort study. Am. J. Obstet. Gynecol.226, 714.e1–714.e16. 10.1016/j.ajog.2021.11.1374
42
MadanJ.ChenM.GoodmanE.DavisJ.AllanW.DammannO. (2010). Maternal obesity, gestational hypertension, and preterm delivery. J. Maternal-Fetal and Neonatal Med.23, 82–88. 10.3109/14767050903258738
43
Martínez-GarcíaM. Á.Luque-RamírezM.San-MilĺanJ. L.Escobar-MorrealeH. F. (2009). Body iron stores and glucose intolerance in premenopausal women: role of hyperandrogenism, insulin resistance, and genomic variants related to inflammation, oxidative stress, and iron metabolism. Diabetes Care32, 1525–1530. 10.2337/DC09-0420
44
MattssonK.Nilsson-CondoriE.ElmerstigE.VassardD.SchmidtL.ZiebeS.et al (2021). Fertility outcomes in women with pre-existing type 2 diabetes—a prospective cohort study. Fertil. Steril.116, 505–513. 10.1016/J.FERTNSTERT.2021.02.009
45
MengstieM. A.Chekol AbebeE.Behaile TeklemariamA.Tilahun MuluA.AgidewM. M.Teshome AzezewM.et al (2022). Endogenous advanced glycation end products in the pathogenesis of chronic diabetic complications. Front. Mol. Biosci.9, 1002710. 10.3389/fmolb.2022.1002710
46
MerhiZ. (2014). Advanced glycation end products and their relevance in female reproduction. Hum. Reprod.29, 135–145. 10.1093/humrep/det383
47
MerhiZ.IraniM.DoswellA. D.AmbroggioJ. (2014). Follicular fluid soluble receptor for advanced glycation end-products (sRAGE): a potential indicator of ovarian reserve. J. Clin. Endocrinol. Metab.99, E226–E233. 10.1210/jc.2013-3839
48
MerhiZ.KandarakiE. A.Diamanti-KandarakisE. (2019). Implications and future perspectives of AGEs in PCOS pathophysiology. Trends Endocrinol. Metab.30, 150–162. 10.1016/j.tem.2019.01.005
49
MirF. A.AbdesselemH. B.CyprianF.IskandaraniA.DoudinA.ShraimM. A. R.et al (2025). Metabolically healthy obesity is characterized by a distinct proteome signature. Int. J. Mol. Sci.26, 2262. 10.3390/ijms26052262
50
Mohammadian KhonsariN.KhashayarP.ShahrestanakiE.KelishadiR.Mohammadpoor NamiS.Heidari-BeniM.et al (2022). Normal weight obesity and cardiometabolic risk factors: a systematic review and meta-analysis. Front. Endocrinol. (Lausanne)13, 857930. 10.3389/fendo.2022.857930
51
MoustakliE.StavrosS.KatopodisP.PotirisA.DrakakisP.DafopoulosS.et al (2025). Gut microbiome dysbiosis and its impact on reproductive health: mechanisms and clinical applications. Metabolites15, 390. 10.3390/METABO15060390
52
MuhammadT.WanY.LvY.LiH.NaushadW.ChanW. Y.et al (2023). Maternal obesity: a potential disruptor of female fertility and current interventions to reduce associated risks. Obes. Rev.24, e13603. 10.1111/obr.13603
53
NejabatiH. R.MotaA.FarzadiL.GhojazadehM.FattahiA.HamdiK.et al (2017). Follicular fluid PlGF/sFlt-1 ratio and soluble receptor for advanced glycation end–products correlate with ovarian sensitivity index in women undergoing A.R.T. J. Endocrinol. Invest40, 207–215. 10.1007/s40618-016-0550-5
54
NiuZ.LinN.GuR.SunY.FengY. (2014). Associations between insulin resistance, free fatty acids, and oocyte quality in polycystic ovary syndrome during in vitro fertilization. J. Clin. Endocrinol. Metab.99, E2269–E2276. 10.1210/JC.2013-3942
55
PenziasA.AzzizR.BendiksonK.FalconeT.HansenK.HillM.et al (2021). Obesity and reproduction: a committee opinion. Fertil. Steril.116, 1266–1285. 10.1016/J.FERTNSTERT.2021.08.018
56
PerroneA.GiovinoA.BennyJ.MartinelliF. (2020). Advanced glycation end products (AGEs): biochemistry, signaling, analytical methods, and epigenetic effects. Oxid. Med. Cell Longev.2020, 3818196. 10.1155/2020/3818196
57
PetersonM. D.Al SnihS.StoddardJ.ShekarA.HurvitzE. A. (2014). Obesity misclassification and the metabolic syndrome in adults with functional mobility impairments: nutrition Examination Survey 2003–2006. Prev. Med. Balt.60, 71–76. 10.1016/J.YPMED.2013.12.014
58
PhelpsN. H.SingletonR. K.ZhouB.HeapR. A.MishraA.BennettJ. E.et al (2024). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet403, 1027–1050. 10.1016/S0140-6736(23)02750-2
59
PlutaW.DudzińskaW.LubkowskaA. (2022). Metabolic obesity in people with normal body weight (MONW)—review of diagnostic criteria. Int. J. Environ. Res. Public Health19, 624. 10.3390/ijerph19020624
60
QiX.YunC.SunL.XiaJ.WuQ.WangY.et al (2019). Gut microbiota–bile acid–interleukin-22 axis orchestrates polycystic ovary syndrome. Nat. Med.25 (8), 1225–1233. 10.1038/s41591-019-0509-0
61
QiL.TianY.ChenY. (2021). Circulating bile acid profiles: a need for further examination. J. Clin. Endocrinol. Metab.106, 3093–3112. 10.1210/clinem/dgab531
62
QiL.LiuY.WangS.ShiH.ChenX.WangN.et al (2022). Abnormal BMI in male and/or female partners are deleterious for embryonic development and pregnancy outcome during ART process: a retrospective study. Front. Endocrinol.13, 856667. 10.3389/fendo.2022.856667
63
QinX.DuJ.HeR.LiY.ZhuQ.LiY.et al (2023). Adverse effects of type 2 diabetes mellitus on ovarian reserve and pregnancy outcomes during the assisted reproductive technology process. Front. Endocrinol. (Lausanne)14, 1274327. 10.3389/fendo.2023.1274327
64
RichardsonM. C.CameronI. T.SimonisC. D.DasM. C.HodgeT. E.ZhangJ.et al (2005). Insulin and human chorionic gonadotropin cause a shift in the balance of sterol regulatory element-binding protein (SREBP) isoforms toward the SREBP-1c isoform in cultures of human granulosa cells. J. Clin. Endocrinol. Metab.90, 3738–3746. 10.1210/jc.2004-2057
65
RomualdiD.AtaB.BhattacharyaS.BoschE.CostelloM.GersakK.et al (2023). Evidence-based guideline: unexplained infertility. Hum. Reprod.38, 1881–1890. 10.1093/HUMREP/DEAD150
66
RudermanN.ChisholmD.Pi-SunyerX.SchneiderS. (1998). The Metabolically Obese, Normal-Weight Individual R e v i s i t e d. Diabetes47, 699–713. 10.2337/diabetes.47.5.699
67
SamS. (2007). Obesity and polycystic ovary syndrome. Obes. Manag.3, 69–73. 10.1089/OBE.2007.0019
68
SatyaraddiA.Elizabeth CherianK.KapoorN.Thaiparambil KunjummenA.KamathM. S.ThomasN.et al (2019). Body composition, metabolic characteristics, and insulin resistance in obese and nonobese women with polycystic ovary syndrome. J. Hum. Reprod. Sci.12, 78–84. 10.4103/jhrs.JHRS_2_19
69
SekarN.GarmeyJ. C.VeldhuisJ. D. (2000). Mechanisms underlying the steroidogenic synergy of insulin and luteinizing hormone in porcine granulosa cells: joint amplification of pivotal sterol-regulatory genes encoding the low-density lipoprotein (LDL) receptor, steroidogenic acute regulatory (StAR) protein and cytochrome P450 side-chain cleavage (P450scc) enzyme. Mol. Cell Endocrinol.159, 25–35. 10.1016/S0303-7207(99)00203-8
70
SilvestrisE.de PergolaG.RosaniaR.LoverroG. (2018). Obesity as disruptor of the female fertility. Reproductive Biol. Endocrinol.16, 22. 10.1186/s12958-018-0336-z
71
ŠimjákP.CinkajzlováA.AnderlováK.ParízekA.MrázM.KršekM.et al (2018). The role of obesity and adipose tissue dysfunction in gestational diabetes mellitus. J. Endocrinol.238, R63–R77. 10.1530/JOE-18-0032
72
SmeenkJ.WynsC.De GeyterC.KupkaM.BerghC.SaizI. C.et al (2023). ART in Europe, 2019: results generated from European registries by ESHRE. Hum. Reprod.38, 2321–2338. 10.1093/HUMREP/DEAD197
73
SmithG. I.MittendorferB.KleinS. (2019). Metabolically healthy obesity: facts and fantasies. J. Clin. Invest129, 3978–3989. 10.1172/JCI129186
74
TakaeK.NakataM.WatanabeT.SasadaH.FujiiH.TomiokaI. (2019). Evidence for the involvement of FXR signaling in ovarian granulosa cell function. J. Reproduction Dev.65, 47–55. 10.1262/jrd.2018-054
75
TangJ.XuY.WangZ.JiX.QiuQ.MaiZ.et al (2023). Association between metabolic healthy obesity and female infertility: the national health and nutrition examination survey, 2013–2020. BMC Public Health23, 1524–1529. 10.1186/s12889-023-16397-x
76
ThongE. P.CodnerE.LavenJ. S. E.TeedeH. (2020). Diabetes: a metabolic and reproductive disorder in women. Lancet Diabetes Endocrinol.8, 134–149. 10.1016/S2213-8587(19)30345-6
77
VazzanaN.GuagnanoM. T.CuccurulloC.FerranteE.LattanzioS.LianiR.et al (2012). Endogenous secretory RAGE in obese women: association with platelet activation and oxidative stress. J. Clin. Endocrinol. Metab.97, E1726–E1730. 10.1210/jc.2012-1473
78
VítekL.HaluzíkM. (2016). The role of bile acids in metabolic regulation. J. Endocrinol.228, R85–R96. 10.1530/JOE-15-0469
79
WeiY.ChengJ.LuoM.YangS.XingQ.ChengJ.et al (2022). Targeted metabolomics analysis of bile acids and cell biology studies reveal the critical role of glycodeoxycholic acid in buffalo follicular atresia. J. Steroid Biochem. Mol. Biol.221, 106115. 10.1016/J.JSBMB.2022.106115
80
YaoX.DongS.GuanW.FuL.LiG.WangZ.et al (2023). Gut microbiota-derived short chain fatty acids are associated with clinical pregnancy outcome in women undergoing IVF/ICSI-ET: a retrospective study. Nutrients15, 2143. 10.3390/NU15092143
81
YaoY.LiuW.ZhangX.SuN.HuangL.NongY.et al (2024). Normal weight obesity is associated with lower AFC and adverse IVF outcomes. Front. Endocrinol. (Lausanne)15, 1332995. 10.3389/fendo.2024.1332995
82
YeM.YangY.CaiC.LiZ.QiuA.HeJ.et al (2025). Association between female waist-hip ratio and live birth in patients undergoing in vitro fertilization: a retrospective cohort study. Front. Endocrinol. (Lausanne)16, 1537360. 10.3389/fendo.2025.1537360
83
YuJ.ZhangY.ZhuY.LiY.LinS.LiuW.et al (2023). Circulating bile acid profile characteristics in PCOS patients and the role of bile acids in predicting the pathogenesis of PCOS. Front. Endocrinol. (Lausanne)14, 1239276. 10.3389/fendo.2023.1239276
84
YuanS.SheD.JiangS.DengN.PengJ.MaL. (2024). Endoplasmic reticulum stress and therapeutic strategies in metabolic, neurodegenerative diseases and cancer. Mol. Med.30 (1), 40–15. 10.1186/S10020-024-00808-9
85
ZhangB.ShenS.GuT.HongT.LiuJ.SunJ.et al (2019). Increased circulating conjugated primary bile acids are associated with hyperandrogenism in women with polycystic ovary syndrome. J. Steroid Biochem. Mol. Biol.189, 171–175. 10.1016/J.JSBMB.2019.03.005
86
ZhangY.HeC.HeY.ZhuZ. (2025). Follicular fluid metabolomics: tool for predicting IVF outcomes of different infertility causes. Reprod. Sci.32, 921–934. 10.1007/S43032-024-01664-Y
87
ZhengQ.LinW.LiuC.ZhouY.ChenT.ZhangL.et al (2020). Prevalence and epidemiological determinants of metabolically obese but normal-weight in Chinese population. BMC Public Health20, 487. 10.1186/s12889-020-08630-8
88
ZhuS.WangZ. M.ShenW.HeymsfieldS. B.HeshkaS. (2003). Percentage body fat ranges associated with metabolic syndrome risk: results based on the third National Health and Nutrition Examination Survey (1988–1994). Am. J. Clin. Nutr.78, 228–235. 10.1093/AJCN/78.2.228
89
ZhuW.ChengX.ZhangH.LiJ.LiL.WeiH.et al (2025). Cholic acid inhibits ovarian steroid hormone synthesis and follicular development through farnesoid X receptor signaling in mice. Int. J. Biol. Macromol.301, 140458. 10.1016/J.IJBIOMAC.2025.140458
90
ZhuangJ.WangY.WangS.HuR.WuY. (2024). Association between visceral adiposity index and infertility in reproductive-aged women in the United States. Sci. Rep.14 (1), 14230–14238. 10.1038/s41598-024-64849-0
Summary
Keywords
infertility, metabolism, reproduction, IVF, biomarker
Citation
Berger N, Brugger K and Fluhr H (2025) Metabolic state and female fertility in ART cycles: a summary of current advances. Front. Cell Dev. Biol. 13:1645127. doi: 10.3389/fcell.2025.1645127
Received
11 June 2025
Accepted
27 August 2025
Published
23 September 2025
Volume
13 - 2025
Edited by
Ariane Zamoner, Federal University of Santa Catarina, Brazil
Updates
Copyright
© 2025 Berger, Brugger and Fluhr.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Natascha Berger, natascha.berger@medunigraz.at
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.